NasdaqGM:SGMTBiotechs
A Look At Sagimet Biosciences (SGMT) Valuation After Acne Trial Plans And Equity Raise
Trending interest in Sagimet Biosciences (SGMT) centers on its recent acne pipeline update, with plans to file an IND for denifanstat and to move both denifanstat and TVB-3567 into later stage clinical trials.
See our latest analysis for Sagimet Biosciences.
Those acne trial plans and the recent follow on equity raise come after a sharp run in the shares, with a 30 day share price return of 53.68% and a 1 year total shareholder return of 104.33% from a latest share price of US$8.03. This...